Botulism News and Research

RSS
Botulism is a rare but serious paralytic illness caused by botulinum toxin, which is produced by the bacterium ''Clostridium botulinum''. The toxin enters the body in one of four ways: by colonization of the digestive tract by the bacterium in children (infant botulism) or adults (adult intestinal toxemia), by ingestion of toxin from foodstuffs (foodborne botulism) or by contamination of a wound by the bacterium (wound botulism).
Neogen fiscal 2010 net income increases 26% to $17.5M

Neogen fiscal 2010 net income increases 26% to $17.5M

Cangene eliminated from ARS contract

Cangene eliminated from ARS contract

Cangene announces development of Immune Globulin Intravenous product

Cangene announces development of Immune Globulin Intravenous product

Cangene third-quarter revenues decline 39% to $41.1M

Cangene third-quarter revenues decline 39% to $41.1M

Botox reduces short-term pain in thoracic outlet syndrome patients

Botox reduces short-term pain in thoracic outlet syndrome patients

SQI Diagnostics second-quarter net loss increases to $2,021,000

SQI Diagnostics second-quarter net loss increases to $2,021,000

The Toronto Stock Exchange accepts Cangene's normal course issuer bid

The Toronto Stock Exchange accepts Cangene's normal course issuer bid

SQI Diagnostics signs development agreement with Silliker

SQI Diagnostics signs development agreement with Silliker

Cangene extends botulism antitoxin contract with BARDA

Cangene extends botulism antitoxin contract with BARDA

Cangene receives European Commission approval to market ImmunoGam

Cangene receives European Commission approval to market ImmunoGam

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

Spasticity in flexor muscles of elbow, wrist, and fingers: Botox approved for treatment

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

FDA approves BOTOX for treatment of increased muscle stiffness in adults with upper limb spasticity

New strategy against Botulinum toxin

New strategy against Botulinum toxin

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Three-day interactive conference to showcase new trendsetting techniques and research in aesthetic plastic surgery

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Novel breakthrough may lead to new methods for sterilizing food and medical equipment

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene to acquire U.S. commercialization rights for HepaGam B

Roundtable discussion to elevate awareness about the importance of biopreparedness

Roundtable discussion to elevate awareness about the importance of biopreparedness